Fin Cascade
Get Android appGet iOS app

Prices as of 8 Oct 2026 close · Not investment advice

Eris Lifesciences Limited

NSE: ERISPharmaceuticals

Share price

₹1,155.10

+0.81% close of 8 Oct 2026

Market cap ₹16,171 CrP/E 24.7

Business score

How strong the business is, in one number. The parts behind it are in Pro.

69

out of 100 · worked out 8 Oct 2026

Your ratios

The numbers you want to see first. Tap Edit to change them.

Market cap

₹16,171 Cr

P/E ratio

24.7

P/B ratio

4.1

ROCE

14.1%

ROE

18.7%

Dividend yield

0.6%

Price & valuation chart

How the share price and its valuation have moved. Hover over the chart to see any day. Prices as of the last close.

Prices as of 8 Oct 2026 close52-week high ₹1,701.3052-week low ₹1,145.80

Answers

Simple answers to the questions investors ask most, from the company's own numbers.

How fast it has been growing

Sales grew 9.6% over the past year, and 17.5% a year over its longer record. Meanwhile what it keeps of every 100 rupees of sales improved from 34.9% to 35.3% over the last four years.

Whether it grew faster than its sector

It grew 17.5% a year against a sector median of 13.1% — 4.5 percentage points faster.

Room to re-rate, or risk of de-rating

At 24.7× earnings against a market that pays 23.9× across 2199 companies we can price. Its own industry sits at 78.7×, across 5 companies. It is against its own five-year median of 31.7×, the 23rd percentile of its own range.

Whether growth justifies the valuation

Priced at 1.3 times its growth rate, on earnings growth of 19%.

Profit growthPrice per ₹1 profitPer 1% growth
Eris Lifesciences Limited — this one19%/yr24.7×₹1.3
Sun Pharmaceutical13%/yr33.4×₹2.6
Divi's Laboratories13%/yr83.3×₹6.4
Torrent Pharmaceuticals22%/yr78.7×₹3.6
Zydus Lifesciences32%/yr23.1×₹0.72
Laurus Labs Limited4%/yr98.6×₹24.7

Compared with companies filed under the same label. That grouping comes from the exchange's filing category, so some of them may not be real rivals.

How it compares with its peers

Against companies the exchange files under the same label (Pharmaceuticals), it ranks 67 of 130 on returns, 29 of 127 on growth, 8 of 130 on margin. That grouping comes from the exchange's filing category, so some of them may not be real rivals.

What makes it hard to beat — and is that still true?

No durable advantage shows in the numbers: it earns 14.1% on capital, ahead of 48% of companies filed under the same label. That grouping comes from the exchange's filing category, so some of them may not be real rivals.

Whether its growth pays for itself

Yes — Over the last five years it made ₹2759 crore of cash from the business and spent ₹1542 crore on plant and equipment, with ₹1217 crore to spare; it still raised ₹828 crore mostly borrowed — borrowings rose from ₹84 crore to ₹2359 crore. And the profit is real: of every 100 rupees it reported over 12 years, about 110 arrived as cash (before interest, which is why it can exceed the profit). Its cash comes back faster than it used to: it went from being waiting 75 days for its cash to paid 71 days before it paid its own suppliers.

Profit reality check

Is the profit real cash? Simple checks on the accounts. Facts only, not advice.

6 of 9 checks clear · 67%

Latest result · Q1 FY27

What the last results showed. Whether management kept its word is in Pro.

Revenue grew 13% on a year ago, with profit margin running below the 36% promised for the full year

Announced 29 Jul 2026 · Consolidated · Unaudited

Revenue

₹873 Cr

Revenue vs last year

+13.0%

Revenue vs last quarter

+15.4%

Net profit

₹143 Cr

Profit vs last year

+14.7%

Profit vs last quarter

-48.6%

Net margin

16.4%

EPS

₹10.28

Checklist before you investPRO

Points for and against, in one list.

Key numbers & peers

The main numbers grouped by topic, and how the company compares with similar ones.

Price

Market cap
₹16,171 Cr
Prev close
₹1,155.10
52w High
₹1,740
52w Low
₹1,141
Enterprise value
₹18,315 Cr
Beta
0.6
Price CAGR 1y
-28.0%
Price CAGR 3y
9.0%
Price CAGR 5y
8.0%
Price CAGR 10y
—

Ratios

Return on assets
9.1%
PEG ratio
1.3
P/E ratio
24.7
P/B ratio
4.1
EV / EBITDA
16.4
Industry P/E
38.0
ROCE
14.1%
ROCE 5y average
15.8%
ROE
18.7%
Debt / Equity
0.6
Interest coverage
4.3
Dividend yield
0.6%
ROE 3y average
16.0%
ROE last year
19.0%

Annual P&L

Annual revenue
₹3,129 Cr
Annual profit
₹648 Cr
Operating margin
36.0%
Net profit margin
20.7%
EBITDA margin
35.8%
Sales growth 3y
22.9%
Sales growth 5y
20.9%
Profit growth 3y
19.0%
Profit growth 5y
12.0%
EPS
₹44.7
Sales growth TTM
10.0%
Profit growth TTM
69.0%
Dividend payout
16.0%

Quarter P&L

Sales latest quarter
₹873 Cr
Profit latest quarter
₹143 Cr
YoY quarterly sales growth
13.0%
YoY quarterly profit growth
14.4%
OPM latest quarter
33.9%

Balance Sheet

Book Value
₹279
Face Value
₹1.0
Total debt
₹2,359 Cr
Total cash
₹67 Cr
Borrowings
₹2,359 Cr
Reserves / Equity
277.8

Cash Flow

Operating cash flow
₹538 Cr
Free cash flow
₹241 Cr
FCF yield
0.3%
Net cash flow
-₹145 Cr

Shareholding

Promoter holding
54.1%
FII holding
5.8%
DII holding
20.7%
Public holding
19.4%

Peer comparison

CompanyPrice ₹P/EMkt cap ₹ CrDiv yield %Profit qtr ₹ CrProfit var %Sales qtr ₹ CrSales var %ROCE %
Sun Pharma.Inds.1,781.0033.84,27,3220.902,901.26.015,299.910.520.5
Divi's Lab.9,588.0085.42,54,5310.31902.065.53,080.027.822.0
Torrent Pharma.4,716.2080.41,79,3890.81566.05.84,921.054.915.2
Zydus Lifesci.1,153.0023.61,15,0120.09990.2-35.18,017.022.021.1
Laurus Labs2,052.80101.41,10,9150.10362.1125.52,026.329.117.8
Cipla1,327.2030.01,07,2210.98785.6-39.27,119.32.315.5
Mankind Pharma2,500.0048.41,03,2610.04574.129.64,030.612.913.5
ERIS Lifescience1,145.8024.215,8970.63143.320.7873.313.014.1
Median417.9034.52,2080.0713.529.5164.018.415.0

Competes with: Aurobindo Pharma, Cipla, Divi's Laboratories, Dr Reddy's Laboratories, Laurus Labs Limited, Lupin, Mankind Pharma Limited, Sun Pharmaceutical, Torrent Pharmaceuticals, Zydus Lifesciences

Quarterly results

Sales and profit for each of the last 13 quarters. Newest on the right. ₹ crore.

Consolidated · to 30 Jun 2026
Line itemJun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Sales467505486551720741727705773792807757873
Expenses297324311402470477477453496504526484577
Material Cost6870831066894
Change in Inventories5.9910-260.21-5.8414
Purchases of Stock-in-Trade96104146117123131
Employee Cost121144137138137153
Other Expenses161167164164161184
Operating Profit170181176148250265250252277288282272296
OPM %36363627353634363636353634
Other Income13415254843-1722
Exceptional items (within Other Income)000-1700
Interest17161833605957544950494647
Depreciation41424654768081777169707072
Profit before tax11212611677116129116129161173145159179
Tax %17312-422252521222225-7520
Net Profit9412210180909687102125134109279143
EPS in Rs6.989.077.555.226.126.736.156.898.668.827.322010
Diluted EPS in Rs6.898.648.817.312110

Profit & loss

Yearly sales, costs and profit for 12 years, plus the last 12 months (TTM). ₹ crore.

Consolidated · to 31 Mar 2026
Line itemMar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales5465977508569821,0741,2121,3471,6852,0092,8943,1293,230
Expenses4274254805336377027818581,1461,3321,8762,0092,092
Material Cost276327
Change in Inventories-35-22
Purchases of Stock-in-Trade473491
Employee Cost505557
Other Expenses657657
Operating Profit1181722693223453724314895396771,0181,1201,138
OPM %22293638353536363234353635
Other Income732526311292292218-9-9
Exceptional items (within Other Income)0-17
Interest00111232242685231193191
Depreciation1620232636504365117183315280281
Profit before tax109154270312317331394442405431489639657
Tax %1813968111088823-1
Net Profit89135247295291297355406374397375648666
EPS in Rs6,4899,7141821212226302829264547
Diluted EPS in Rs2645
Dividend Payout %0630001321202602816

Compounded growth

Average yearly growth over different spans, as stored. A span can cross a demerger or an acquisition.

Compounded sales growth

10 years
18%
5 years
21%
3 years
23%
TTM
10%

Compounded profit growth

10 years
17%
5 years
12%
3 years
19%
TTM
69%

Stock price CAGR

10 years
—
5 years
8%
3 years
9%
1 year
-28%

Return on equity

10 years
21%
5 years
18%
3 years
16%
Last year
19%

Balance sheet

What the company owns and what it owes, at the end of each year. ₹ crore.

Consolidated
Line itemMar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital0.140.1414141414141414141414
Reserves2662995538481,1371,2831,5631,8952,1822,5732,8413,889
Borrowings10137717607848772,7812,4782,359
Other Liabilities91981241701752052022333371,3661,415861
Minority Interest417-7.01
Total Liabilities3573976921,4081,5021,5021,7852,2263,4106,7346,7477,123
Fixed Assets72712327717618758549182,5684,3195,3065,188
CWIP000034227222067171
Investments1671903033653567829452037166762
Other Assets1191361572713835446367617832,3791,3071,702
Total Assets3573976921,4081,5021,5021,7852,2263,4106,7346,7477,123

Cash flows

Real money coming in and going out each year — from the business, from investments and from loans. ₹ crore.

Consolidated
Line itemMar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Cash from Operating Activity901312002352232713753782924861,065538
Cash from Investing Activity-92-44-184-590-5123-323-320-975-1,828-78-369
Cash from Financing Activity0-84-24363-221-335-82-456881,380-881-314
Net Cash Flow-24-88-360-3014538105-145
Free Cash Flow77108150210186125350258-550357910241

Ratios

How fast customers pay, how long stock sits, and how well capital earns — year by year.

Consolidated
Line itemMar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days161624283153424463775879
Inventory Days223178195178196148145166136182171200
Days Payable14292134247200213157166129210170151
Cash Conversion Cycle9710284-4028-123044704859129
Working Capital Days15923-13-1759647550-296-49-71
ROCE %475360342625272517111214

Shareholding pattern

Who owns the company — founders (promoters), foreign funds, Indian funds and the public. In %.

Consolidated · to 30 Jun 2026
Line itemSep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Promoters555555555555555555555454
FIIs131314158.018.368.438.397.216.856.395.76
DIIs151516161918181819202021
Public171715141819191919181919
No. of Shareholders42,24546,49651,75344,17646,34653,31450,08752,22559,43854,71351,65650,798

Price trend

The price as a Renko brick chart: small moves drop out so the bigger path stands out.

Change over 1 year -27.5% (₹1,592.40 → ₹1,155.10)Brick size ₹42.01 (fixed)Bricks 30
₹1,400₹1,600₹1,155Dec '25Mar '26Jun '26Sep '26
Price moved up one brickPrice moved down one brickLast close ₹1,155.10 on 8 Oct 2026

Every brick is the same size, about one typical day's move. A new brick needs a full brick's move; turning the other way needs two. Bricks show where the price went, not where it will go.

Open interestPRO

Where option traders are positioned on this stock.

Industry numbers

The numbers that matter most in this industry, from the company's own filings.

1 when an audit qualification is filed as repetitive

0.00flag

2026-03-31

the company's own unlisted debt securities in default at period end

0.00cr

2026-06-30

the company's own loans / revolving facilities in default at period end (standalone filing)

0.00cr

2026-06-30

guarantees / comfort given for promoter, promoter group, directors and KMP

0.00cr

2026-03-31

loans outstanding to promoter, promoter group, directors and KMP (governance filing)

0.00cr

2026-03-31

security given for the borrowing of promoter, promoter group, directors and KMP

0.00cr

2026-03-31

FY revenue / permanent employees + workers, same basis (calc)

66,05,294inr

2026-03-31

News

News and filings about Eris Lifesciences Limited. Open one to see why it matters.

No recent news for this company.

Supply chain

Who it buys from, sells to and competes with — as recorded in our map of company links.

Competes with

Buys drug ingredients from

Buys from

About

What the company is, from our own records: where it sits, where it makes things, and what it is made of.

Sector
Healthcare
Industry
Pharmaceuticals
Classification
Healthcare › Pharmaceuticals
ISIN
INE406M01024

Plants

  • Eris Bhopal insulin/biosimilar plant
  • Eris Lifesciences Guwahati facility · Guwahati, Assam
  • Swiss Parenterals Unit I · Ahmedabad, Gujarat
  • Swiss Parenterals Unit II · Ahmedabad, Gujarat

News impact

Big market events that reach Eris Lifesciences Limited, and how the effect spreads.

No recent market events reach this company.

Dividends, splits & big trades

Money paid out, share splits and buybacks, and big buys or sells by funds and insiders.

Dividends

29 May 2026interim₹7.21
13 Feb 2025interim₹7.35
11 Aug 2022interim₹7.35
5 Aug 2021interim₹6.01
13 Aug 2020interim₹5.5
19 Mar 2020interim₹2.87

Splits, bonuses & buybacks

  • daily-prices repair: 7 rows from NSE's archive (replace 1, delete 0, insert 6), 2020-02-01..2026-02-01 (docs/flat_day_repair.md)1× · 1 Feb 2020

Documents

Annual reports, results presentations and earnings calls, straight from the source.

Facts from company filings and exchange data. Not investment advice: nothing here tells you to buy or sell.